• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Expert Insights into Emerging Oral Psoriasis Treatments

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

Panelists:

Linda Stein-Gold, MD

Henry Ford Health

Detroit, Michigan

Mona Shahriari, MD

Yale University

New Haven, Connecticut

Micheal Cameron, MD, FAAD

Cameron Dermatology

New York, New York

Leon Kircik, MD

DermResearch, PLLC

Louisville, Kentucky

George Han, MD

Hofstra University

Long Island, New York

Program Description:

Experts in the management of skin conditions discuss the latest developments in plaque psoriasis management, covering emerging oral therapies, novel topical treatments, and advancements in biologic therapy. The discussion provides practical insights for healthcare professionals to integrate these innovations into daily clinical practice for optimal patient outcomes. Additionally, the panel addresses the strategic placement of emerging therapies within current treatment guidelines, ensuring participants stay informed about the evolving landscape of psoriasis care.

Segment Description:

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

Related Videos
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
© 2024 MJH Life Sciences

All rights reserved.